|“||A new day, every day.||”|
A byproduct of humanity's unceasing search for eternal life, Asclepitrin is marketed as a "wonder-drug", an amazing step forward in medicine by allowing humans to exceed the Hayflick limit of the cells in the human body and potentially prolong a person's life near indefinitely. Incredibly expensive and difficult to make, the little-known secret of Asclepitrin is in it's origins. While largely advertised as a happy accident in the development of cancer inhibiting drugs, the drug is actually made and continues to be made through the harvesting and the ceaseless processing of the Faenix species, who's telomerese rebuilding enzymes have continued to be proven impossible to synthesize otherwise.
However, Asclepitrin is far from a permanent solution to aging, however. The drug is only effective with consistent and frequent treatment under a strict time-table, but this also prompts a reliance on the drug. While it has almost no addictive qualities whatsoever, the drug begins to inhabit specific zones it creates called TDR sets, both why it's so successful and why it's so potentially dangerous. Asclepitrin, without fail, rebuilds and repairs telomeres, and only rebuilds and repairs them. While this doesn't sound dangerous in and of itself, it's taken to the greatest extreme this concept can go. It will attack telomerese strands, regardless of their status and then replace them, breaking them apart and rebuilding them in a much more tenuous bond within their TDR sets (Telomerese Destruction and Reconstruction). If there is no consistent supply of Asclepitrin, these replacement telomeres break apart and metabolize. The result is instant detioration of the user, and an accelerated progression into old age until the cells cease replication entirely and the subject subsequently dies. The affliction is worsened through the presence of the TDR sets, which, without it's target of telomeres, begin to undergo crisis. In short order, the TDR sets begin attacking their host cells, and perhaps most dangerously deactivate the p53 and pRb pathways. At this stage, any recovery is impossible to achieve, even with additional treatment of Asclepitrin. The deactitvation of these pathways prompt near total cellular death and significant chromosomal changes.
Asclepitrin is only recommended after a long series of tests, as it's been proven only to work with a specific set of genetic markers. Current studies indicate that only twenty-six percent of humans actually carry these markers, for whatever reason, and consuming the drug without these markers ends in total and regularly fatal rejection.